Clopidogrel Before PCI Improves Outcomes

BY MITCHEL L. ZOLER
Philadelphia Bureau

STOCKHOLM — Clopidogrel pretreatment markedly reduced the rate of cardiovascular events in patients with ST-segment elevation MI who underwent percutaneous coronary interventions in a study with more than 1,800 patients.

On the basis of these and previous findings, clopidogrel pretreatment should be considered the standard of care for all patients undergoing PCI, Marc S. Sabatine, M.D., said at the annual congress of the European Society of Cardiology.

Until now, usual care has been to administer a loading dose of clopidogrel when PCI begins, he said in an interview.

For every 23 patients in the study, pretreatment with clopidogrel prevented one major cardiovascular event. "That is an amazingly big benefit from one to three extra doses of clopidogrel," commented Christopher P. Cannon, M.D., a cardiologist at Brigham and Women's Hospital in Boston and a coinvestigator on the study.

Even if clopidogrel is not given at initial presentation, it should be started once the decision is made to perform coronary angiography, said Dr. Sabatine, also a cardiologist at the hospital.

The study was sponsored by Sanofi-Aventis and Bristol-Myers Squibb, which market clopidogrel (Plavix) worldwide. Dr. Sabatine and Dr. Cannon have received honoraria and research support and have been advisers to both companies.

Clopidogrel pretreatment was effective both before and after PCI was performed, noted Keith Fox, M.B., professor of cardiology at the University of Edinburgh. "The most convincing evidence [of clopidogrel's efficacy] is the consistency of the clinical effect" across all subgroups examined in the study, he commented.

The new analysis was a prespecified substudy of the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study. Results from the parent study, which involved nearly 3,500 patients, showed that patients who had a STEMI and initially received thrombolytic therapy had better outcomes when a clopidogrel regimen was begun immediately, along with the first dose of aspirin and the thrombolytic agent (N. Engl. J. Med. 2005;352:1179-89).

All patients in the CLARITY study were

Equivocal Data on Peripheral Drug-Eluting Stents

LAS VEGAS — Drug-eluting stents have not worked as well in the peripheral vasculature as they have in the coronary arteries, but that doesn't mean that investigations should be abandoned, Gary Ansel, M.D., said at a meeting on vascular interventions sponsored by Medical Media Communications.

So far, clinical trials in which drug-eluting stents were compared with bare stents in the periphery have shown that restenosis in distant vessels is a different process, said Dr. Ansel, a peripheral vascular disease specialist who practices in Columbus, Ohio.

Trials in the renal arteries and the superficial femoral artery have not shown any demonstrable benefit from drug elution, but there has been some indication of benefit. In addition, most of the trials have been small and, therefore, not definitive.

The findings of the Sirolimus-Coated Cordis SMART Nitinol Self-Expanding Stent for the Treatment of Obstructing Superficial Femoral Artery Disease (SIROCCO) trial, for example, suggested that the drug sirolimus might have had some positive benefit for distant vessels, and that a significant benefit might be found with longer follow-up of the patients.

The trials have been complicated by the fact that the bare nitinol stents used for comparison have performed better than was expected at the outset of the trials, Dr. Ansel added.

On the negative side, one study of sirolimus in renal arteries suggested the drug may have an adverse effect on kidney function.

Drugs still considered worth investigating in stent trials include paclitaxel and bisphosphonates.

The way to get better results with stents in the periphery may not be in the use of a different agent, but, rather, in using stents with different drug delivery rates from those in coronary stents, Dr. Ansel said.

—Timothy F. Kirn

New Indication in Heart Failure NYHA Class II-IV and LVEF ≤40%

Add ATACAND today. Because ATACAND can...

Further reduce CV death or HF hospitalization when added to conventional HF therapy including an ACE inhibitor (ACEI)[1]



CHARM-Added was a double-blind, placebo-controlled study of 2548 subjects with NYHA Class II-IV HF and LVEF ≤40% who were randomized to placebo or ATACAND (initially 4-8 mg daily, titrated as tolerated to 32 mg daily) on top of ACE inhibitors and other conventional HF therapies. Median follow-up was 41 months.

ATACAND is indicated for the treatment of heart failure (NYHA Class II-IV) in patients with left-ventricular systolic dysfunction (ejection fraction ≤40%) to reduce cardiovascular death and to reduce heart failure hospitalizations. (See Clinical Trials.) ATACAND also has an added effect on these outcomes when used with an ACE inhibitor.

The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, ATACAND should be discontinued as soon as possible. See WARNINGS, *Fetal/Neonatal Morbidity and Mortality.*

Please see adjacent brief summary of full Prescribing Information, including boxed WARNING regarding use in pregnancy.

Once-A-Day Tablets
Atacand®
candesartan cilexetil